9/20/2007

China plans to approve imports of a Bayer Healthcare recombinant-clotting factor to ease the country's current medication shortage for hemophilia patients. Officials stressed they are not easing an existing ban on imported blood and plasma-derived products because the treatment is not made from human plasma.

Related Summaries